Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 43 Show results per page	View Search Criteria \| Help With Results

Last Modified: 5/31/2007 First Published: 8/1/2001


1.		Phase I/II Study of Sequential Paclitaxel, Doxorubicin, and Cyclophosphamide Followed By Immunotherapy With Activated T Cells, Interleukin-2, and Sargramostim (GM-CSF) in Women With High-Risk Stage II or III Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				18 and over				Other				RWMC-0633846 NCT00022230

Last Modified: 11/12/2008 First Published: 2/1/2002


2.		Phase I/II Study of Interleukin-12-Primed Activated T Cells in Combination With Fluorouracil, Sargramostim (GM-CSF), and Interferon alfa-2b in Patients With Metastatic Renal Cell or Colorectal Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Completed				18 and over				Other				STLMC-IMM-0104 L-01-108, STLMC-L-01108, NCI-V01-1686, NCT00030342

Last Modified: 10/17/2003 First Published: 10/1/2002


3.		Phase I/II Randomized Study of High-Dose Therapy and Autologous Peripheral Blood Stem Cell Transplantation Followed By Immunotherapy With Costimulated Autologous T Cells Plus Pneumococcal Conjugate Vaccine in Patients With Multiple Myeloma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Supportive care, Treatment				Closed				18 to 80				Other				MSGCC-0065 UPCC-6401, NCI-V02-1709, NCT00046852


4.		Local Treatment of Metastatic Melanoma With Autologous Lymphocytes and the Bispecific Antibody rM28

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				18 to 75				Other				rM28-001 NCT00204594

Last Modified: 10/10/2008 First Published: 10/30/2007


5.		Phase I/II Pilot Study of Cyclophosphamide and Cellular Adoptive Immunotherapy Comprising Autologous CD4+ and CD8+ Antigen-Specific T-Cell Clones With or Without Aldesleukin in Patients With Metastatic Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				18 to 75				NCI				FHCRC-2179.00 6558, NCT00553306

Last Modified: 8/9/2006


6.		Phase II Study of Adjuvant Autologous Lymphocyte Therapy in Patients With High-Risk Renal Cell Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				Over 16				Other				STLMC-BRM-9401 NCI-V94-0514, NCT00002589

Last Modified: 4/20/2007


7.		Phase II Pilot Study of Tumor-Specific p53 or ras Vaccines With or Without Cellular Immunotherapy With Peptide-Activated Lymphocytes Plus Interleukin-2 in Patients With Tumors Expressing Mutant p53 or ras

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				NCI				NCI-95-C-0105A NCI-T94-0096N, T94-0096, NCT00019084

Last Modified: 3/1/2007


8.		Phase II Pilot Study of Tumor-Specific Peptide Vaccination and Interleukin-2 With or Without Autologous T-Cell Transplantation in Pediatric Patients With Recurrent Sarcomas

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				30 and under				NCI				NCI-97-C-0050K NCI-T96-0037, T96-0037, NCT00019279

Last Modified: 5/22/2007 First Published: 3/1/1999


9.		Phase II Study of High-Dose Chemotherapy and Autologous Peripheral Blood Stem Cell Transplantation Followed by Immunotherapy with Autologous T Cells in Patients With Chronic Phase Chronic Myelogenous Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				Not specified				Other				MSGCC-9851 MSGCC-1198006, NCI-V98-1513, NCT00003727

Last Modified: 12/27/2008 First Published: 9/1/1999


10.		Phase II Study of an Autologous Tumor Cell Vaccine and Adoptive Transfer of OKT3-Activated Autologous T Lymphocytes Following Surgery and Chemotherapy in Patients With Stage III or IV Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI				WSU-C-1403-BR NCI-G99-1561, NCT00004018

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute